

Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated

To the Editors:

The review article by Dr. Stebelska¹ is a comprehensive and welcome article, especially regarding the pharmacology of psilocybin/psilocin. These compounds present therapeutic potentials in several psychiatric conditions, including obsessive-compulsive disorder,² anxiety associated with advanced-stage cancer,³ and drug dependence.⁴ In the case of obsessive-compulsive disorder and anxiety associated with advanced-stage cancer, pilot clinical trials have been conducted reporting promising results.^{2,3} Although these pilot studies present limitations, like the small sample size, it should be noted that these are just the first proof-of-concept, exploratory studies.

Nevertheless, even considering these potentials, it seems that they have been minimized in the review by Dr. Stebelska, which, however, seems to emphasize the psychotic potentials of psilocybin and overestimates its potentials for serious adverse reactions.

Regarding the psychotic-like effects, it should be noted that drugs like psilocybin are used to model only some aspects of schizophrenia, and that although there is some degree of resemblance between the early manifestations of schizophrenia or acute schizophrenic episodes and the acute effects of hallucinogenic drugs like psilocybin, a growing consensus has emerged affirming that the dissimilarities between the 2 states are too clear.⁵ The gradual progression of a symptom complex that includes disturbed thought process, depersonalization, and auditory hallucinations, in many cases evolving into a generalized functional incapacitation, is characteristic of schizophrenia.⁶ However, the effects of

hallucinogens are marked by visual alterations and are limited to some hours.⁷

Moreover, prolonged psychotic episodes, as well as psychiatric disorders in general, are rare in ritual and controlled settings where hallucinogens are consumed or administered. Regarding psilocybin, a pooled analysis from 8 double-blind placebo-controlled experimental studies with this compound, conducted between 1999 and 2008, with follow-up between 8 and 16 months and including 110 healthy subjects,⁷ reported that “acute adverse drug reactions occurred only in a relatively small proportion of subjects,” “were all successfully managed by providing interpersonal support,” and “did not need psychopharmacological intervention.” Moreover, “follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis, or other long-term impairment of functioning in any of the subjects.”

Regarding ayahuasca, an Amazonian botanical hallucinogen rich in dimethyltryptamine, which is an alkaloid chemically and pharmacologically related to psilocybin, several double-blind placebo-controlled clinical trials investigating its acute pharmacology have been safely conducted in healthy volunteers in the last decade.⁸ Moreover, the long-term (ie, years or decades) ritual use of ayahuasca by adolescents and adults presents a low level of adverse reactions.⁸ The regular use of the mescaline-containing cactus peyote by Native Americans also presents a good safety profile with no evidence of cognitive or mental health deficits among this population; rather, total lifetime peyote use was associated with overall better mental health.⁹

Furthermore, controversies still persist regarding the potential causal relationship between the use of hallucinogens and psychotic disorders,¹⁰ and LSD and psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs.¹¹ Specifically in the case of psilocybin-containing mushrooms, a recent report affirmed that the use of these mushrooms is relatively safe, as only few and relatively mild adverse effects have been reported.¹²

Finally, a recent study evaluated the association between lifetime use of hallucinogens and current mental health.¹³ No association was found between lifetime use of hallucinogens and any undesirable past year mental health outcomes, including serious psychological distress, mental health treatment, or symptoms of panic disorder, major depressive episode, mania, social phobia, generalized anxiety disorder, agoraphobia, posttraumatic stress disorder, or non-affective psychosis.

Regarding therapeutic potentials, the review by Dr. Stebelska¹ underestimates the potential therapeutic effects of psilocybin/psilocin, suggesting that results from previous human research indicating positive effects could be questioned because volunteers could be prompted by “dishonest” suggestions, that positive effects are “simply ingenuousness,” that research for new treatment options with these compounds are “possibly nonethical,” and that prolonged personality changes “may reflect serious and dangerous ego disorders.”

The original studies criticized by Dr. Stebelska had good methodological rigor, and “dishonest” suggestions are not in line with the quality of the articles. Moreover, clinical trials with psilocybin were all performed in accordance with international declarations concerning experimentation on humans, and all were previously approved by ethics committees. Furthermore, there are abundant past and current animal and human data showing therapeutic potentials of hallucinogens,¹⁴ including for health conditions with limited treatment options, what seems “possibly nonethical” is that law controls placed on these drugs make research into their potential therapeutic uses very difficult.¹⁵

Finally, the opinion that prolonged personality changes “may reflect serious and dangerous ego disorders” is simply not in line with the scientific literature on hallucinogens. Despite the overall excellent quality of the review, the potential therapeutic effects of psilocybin/psilocin are minimized, while possible adverse reactions are overrated.

Rafael G. dos Santos, PhD

Advisory Board, International Center for
Ethnobotanical Education,
Research & Service,
Halsteren, The Netherlands

The author declares no conflict of interest.

REFERENCES

1. Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. *Ther Drug Monit*. 2013;35:420–442.
2. Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry*. 2006;67:1735–1740.
3. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. 2011;68:71–78.
4. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. *Drug Test Anal*. 2012;4:543–555.
5. Carhart-Harris RL, Leech R, Erritzoe D, et al. bin inform a novel hypothesis of early psychosis. *Schizophr Bull*. 2012. doi: 10.1093/schbul/sbs117.
6. Freedman R. Schizophrenia. *N Engl J Med*. 2003;349:1738–1749.
7. Studerus E, Komater M, Hasler F, et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *J Psychopharmacol*. 2011;25:1434–1452.
8. dos Santos RG. Safety and side effects of ayahuasca in humans—an overview focusing on developmental toxicology. *J Psychoactive Drugs*. 2013;45:68–78.
9. Halpern JH, Sherwood AR, Hudson JI, et al. Psychological and cognitive effects of long-term peyote use among Native Americans. *Biol Psychiatry*. 2005;58:624–631.
10. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR)*. 4th ed. Washington, TX: American Psychiatric Press; 2000.
11. van Amsterdam J, Pennings E, Brunt T, et al. Physical harm due to chronic substance use. *Regul Toxicol Pharmacol*. 2013;66:83–87.
12. van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. *Regul Toxicol Pharmacol*. 2011;59:423–429.
13. Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. *PLoS One*. 2013;8:e63972.
14. Vollenweider FX, Komater M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. *Nat Rev Neurosci*. 2010;11:642–651.
15. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. *Nat Rev Neurosci*. 2013;14:577–585.